Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Woman Loses 6-Year Battle With Mouth Tumor
2.
Lesser-known lobular breast cancer on the rise in U.S. women
3.
PSA Often Unchanged With Enzalutamide Progression
4.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
5.
To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.
1.
Understanding Epidural Hematoma: Symptoms, Causes and Treatment
2.
Intelligent Hematopoietic Cell-State Mapping: Transforming Diagnostic Precision and Clinical Decision-Making
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
5.
Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation